Perrigo Nutritional Dip Riles Analysts Amid Record Consumer Sales
This article was originally published in The Tan Sheet
Executive Summary
A 14% decline in nutritional segment sales that slightly hampered Perrigo Co.’s consumer business revenue could affect the firm’s stock valuation if it cannot turn the division around, multiple analysts said. But Perrigo says the dip was expected and temporary,
You may also be interested in...
Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.